Ceramides are a family of lipids constituted by a sphingoid base and a fatty acid. In the skin, they are mainly present in the stratum corneum where, with cholesterol and free fatty acids, they constitute the inter-corneocyte lipids. With the other lipid groups, they play a key role in the formation of dense lamellar structures between adjacent corneocytes, collectively ensuring the vital efficient barrier to water evaporation and protection from foreign agents´ penetration. Changes in ceramide level and relative composition, with potential impairment of lipid arrangement, have been evidenced in different skin conditions and skin diseases. Therefore, use of suitably formulated ceramides has been proposed for topical treatment to help re-structure damaged lipid arrangement and repair impaired skin barrier function. Nonetheless, the formulation of ceramides in products necessitates specific processes such as heating to high temperature before their introduction in the final formula. In this review on the structure, the role and the potential of ceramides for skincare, we point out the necessity of rigorous process when formulating ceramides into the final product. We demonstrate the counterproductive effects of undissolved ceramides on skin barrier repair capacity of the formulas, when assessed in different in vitro models of disrupted skin barrier.

Les céramides sont une famille de lipides constituée d'une base sphingoïde et d'un acide gras. Dans la peau, ils sont principalement présents dans la couche cornée où, avec le cholestérol et les acides gras libres, ils constituent les lipides inter‐cornéocytes. Avec les autres groupes de lipides, ils jouent un rôle clé dans la formation de structures lamellaires denses entre les cornéocytes adjacents, assurant collectivement la barrière efficace vitale contre l'évaporation de l'eau et la protection contre la pénétration des agents étrangers. Des modifications du taux de céramides et de la composition relative, avec une altération potentielle de l'arrangement lipidique, ont été observées dans différentes affections cutanées et maladies cutanées. Par conséquent, l'utilisation de céramides formulés de manière appropriée a été proposée pour un traitement topique afin d'aider à restructurer la disposition des lipides endommagés et à réparer la fonction de barrière cutanée altérée. Néanmoins, la formulation des céramides dans les produits nécessite des processus spécifiques tels que le chauffage à température élevée avant leur introduction dans la formule finale. Dans cette revue sur la structure, le rôle et le potentiel des céramides pour les soins de la peau, nous soulignons la nécessité d'un processus rigoureux lors de la formulation des céramides dans le produit final. Nous démontrons les effets contre‐productifs des céramides non dissous sur la capacité de réparation de la barrière cutanée des formules, lorsqu'ils sont évalués dans différents modèles in vitro de barrière cutanée perturbée.

• Klíčová slova
• ceramides, emulsion, formulation, skin barrier, skin physiology/structure, topical application,
• MeSH
• ceramidy * chemie   MeSH
• kůže * metabolismus   MeSH
• lidé MeSH
• péče o kůži * metody   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• ceramidy * MeSH

A fully automated sequential injection system was tested in terms of its application in liberation testing, and capabilities and limitations were discussed for clotrimazole liberation from three semisolid formulations. An evaluation based on kinetic profiles obtained in short and longer sampling intervals and steady-state flux values were applied as traditional methods. The obtained clotrimazole liberation profile was faster in the case of Delcore and slower for Clotrimazol AL and Canesten cream commercial formulations. The steady-state flux values for the tested formulations were 52 µg cm-2 h-1 for Canesten, 35 µg cm-2 h-1 for Clotrimazol AL, and 7.2 µg cm-2 h-1 for Delcore measured in 4 min sampling intervals. A simplified approach for the evaluation of the initial rate based on the gradient between the second and third sampling points was used for the first time and was found to correspond well with the results of the conventional methods. A comparison based on the ratio of the steady-state flux and the initial rate values for Canesten and Clotrimazol AL proved the similarity of the obtained results. The proposed alternative was successfully implemented for the comparison of short-term kinetic profiles. Consequently, a faster and simpler approach for dissolution/liberation testing can be used.

• Klíčová slova
• Franz cell, clotrimazole, kinetic profile, liberation study, sequential injection analysis,
• MeSH
• antifungální látky analýza   MeSH
• kinetika MeSH
• klotrimazol analýza   MeSH
• laboratorní automatizace metody   MeSH
• pleťový krém MeSH
• příprava léků MeSH
• průtoková injekční analýza metody   MeSH
• uvolňování léčiv MeSH
• Publikační typ
• časopisecké články MeSH
• hodnotící studie MeSH
• Názvy látek
• antifungální látky MeSH
• klotrimazol MeSH

BACKGROUND: Radiation dermatitis is a very common reaction to radiotherapy, affecting approx. 95% of patients with varying intensity. It is crucial to minimize its side effects. The working group that prepared this document includes physicians, nurses, representatives of the Society for Radiation Oncology, Biology and Physics of the Czech Medical Association of J. E. Purkyně, the Supportive Treatment and Care Section of the Czech Society for Oncology of the Czech Medical Association of J. E. Purkyně, the Czech Wound Management Association, the Oncological Section of Czech Association of Nurses, and dermatologists. The document has been approved by the committees of these associations. PURPOSE: Recommendation for preventive and therapeutic skin care of patients undergoing radiotherapy in the Czech Republic.

• Klíčová slova
• guideline, prevention, radiodermatitis, skin care, treatment,
• MeSH
• dermatitida etiologie   prevence a kontrola   terapie   MeSH
• lidé MeSH
• nádory radioterapie   MeSH
• péče o kůži * MeSH
• radioterapie škodlivé účinky   MeSH
• směrnice pro lékařskou praxi jako téma MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: Randomized controlled studies of combination therapies in rosacea are limited. OBJECTIVE: Evaluate the efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (ie, 30-mg immediate-release and 10-mg delayed-release beads) (DMR) versus IVM and placebo for treatment of severe rosacea. METHODS: This 12-week, multicenter, randomized, investigator-blinded, parallel-group comparative study randomized adult subjects with severe rosacea (Investigator's Global Assessment [IGA] score, 4) to receive either IVM and DMR (combination arm) or IVM and placebo (monotherapy). RESULTS: A total of 273 subjects participated. IVM and DMR displayed superior efficacy in reduction of inflammatory lesions (-80.3% vs -73.6% for monotherapy [P = .032]) and IGA score (P = .032). Combination therapy had a faster onset of action as of week 4; it significantly increased the number of subjects achieving an IGA score of 0 (11.9% vs 5.1% [P = .043]) and 100% lesion reduction (17.8% vs 7.2% [P = .006]) at week 12. Both treatments reduced the Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index score, and ocular signs/symptoms and were well tolerated. LIMITATIONS: The duration of the study prevented evaluation of potential recurrences or further improvements. CONCLUSION: Combining IVM and DMR can produce faster responses, improve response rates, and increase patient satisfaction in cases of severe rosacea.

• Klíčová slova
• clear, combination therapy, concomitant use, doxycycline, individualized treatment, ivermectin, rosacea, rosacea treatment, severe rosacea,
• MeSH
• aplikace orální MeSH
• časové faktory MeSH
• dospělí MeSH
• doxycyklin aplikace a dávkování   MeSH
• ivermektin aplikace a dávkování   MeSH
• kombinovaná farmakoterapie metody   MeSH
• kvalita života MeSH
• léky s prodlouženým účinkem aplikace a dávkování   MeSH
• lidé MeSH
• placebo aplikace a dávkování   MeSH
• pleťový krém aplikace a dávkování   MeSH
• rosacea komplikace   diagnóza   farmakoterapie   MeSH
• spokojenost pacientů MeSH
• stupeň závažnosti nemoci MeSH
• tobolky MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• klinické zkoušky, fáze IV MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH
• Názvy látek
• doxycyklin MeSH
• ivermektin MeSH
• léky s prodlouženým účinkem MeSH
• placebo MeSH
• tobolky MeSH

Instrumental human scent analysis is undoubtedly desirable for many forensic as well medical applications. Most of the previous human scent studies were focused on volatile organic compounds (VOCs) which were analysed by head space solid phase micro-extraction gas chromatography/mass spectrometry (HS-SPME-GC/MS). This method is, however, significantly less sensitive to "heavier" less volatile compounds emitted from the human skin. These less volatile organic scent molecules probably create the basis of the individual human scent signature, and therefore, our attention is focused mainly on these "heavier" compounds. The human scent was adsorbed onto purified glass beads and samples were prepared as hexane solutions obtained by extraction from the sampled glass beads. To resolve a lot of very similar molecules, the comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometer (GCxGC-TOFMS) was used to analyse the hexane scent solutions. Using this technique, more than 137 less volatile molecules including organic fatty acids, ketones, aldehydes, simple esters, alcohols, and especially various fatty acid esters with different carbon chains were identified. A considerable number of these molecules were identified in the scent samples for the first time.

• Klíčová slova
• Forensic chemistry, GCxGC–TOFMS, Human scent analysis, Human scent signature, Molecular composition of human scent,
• MeSH
• adsorpce MeSH
• lidé MeSH
• mikroextrakce na pevné fázi metody   MeSH
• pleťový krém chemie   MeSH
• plynová chromatografie s hmotnostně spektrometrickou detekcí přístrojové vybavení   metody   MeSH
• těkavé organické sloučeniny chemie   izolace a purifikace   MeSH
• Check Tag
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• hodnotící studie MeSH
• Názvy látek
• těkavé organické sloučeniny MeSH

Nanosized materials offer promising strategy for topical drug delivery due to their enhancing effect on drug percutaneous transport across the stratum corneum barrier. In this work, polymeric micelles made from hydrophobized hyaluronic acid (HA) were probed for skin delivery. Compared to non-polymeric micelle solutions containing similar drug amount, in vitro skin penetration analysis indicated 3 times larger deposition of drug in the epidermis and 6 times larger drug deposition in the dermis after 5h of topical treatment in Franz diffusion cells. The drug deposition was further increased with prolonged time of topical treatment. Laser confocal microscopy revealed the accumulation of both, the HA forming the vehicle and the payload, in the epidermis and dermis. Although fluorescent labeling of the HA would suggest co-transport of the HA and the drug, loading FRET pair dyes in the micellar core clearly demonstrated gradual micelle disruption with increasing skin depth. Transcellular penetration was the predominant pathway for the loaded drug. The HA polymeric micelles also demonstrated increased bioactivity of loaded compound in vitro and in vivo. In addition, the loaded micelles were found to be stable in cream formulations and thus they have great potential for topical applications for cosmetic and pharmaceutical purposes.

• Klíčová slova
• Hyaluronan, Polymeric micelle, Skin penetration,
• MeSH
• buněčné linie MeSH
• dospělí MeSH
• kožní absorpce * MeSH
• kyselina hyaluronová chemie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• micely * MeSH
• nosiče léků chemie   MeSH
• pleťový krém MeSH
• polymery MeSH
• prasata MeSH
• techniky in vitro MeSH
• uvolňování léčiv MeSH
• zvířata MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• kyselina hyaluronová MeSH
• micely * MeSH
• nosiče léků MeSH
• polymery MeSH

Psoriasis is a chronic inflammatory disease affecting 1-3% of the general population. Due to the chronic nature of the disease, patients suffer from substantial psychosocial impact and impaired quality of life. Dr Michaels® (also branded as Soratinex®), an Australian series of topical herbal products, has been showing promising results for the treatment of patients with chronic plaque psoriasis and consequent improvement in their quality of life. This study aims to access the changes in quality of life of patients with Psoriasis using an Australian series of herbal skin-care products Dr Michaels® (Soratinex®) for psoriasis. The aim of this study is to observe and analyze the impact of Dr Michaels® product family on the quality of life of patients with psoriasis, 566 patients completed the Dermatology Quality of Life Index (DQLI) questionnaire in their initial consultation and at 3 follow up consultations, over a 6 months period. At the end of the data collection, all patients’ answers were recorded and analyzed. The Psoriasis Area and Severity (PASI) Index were used to measure the severity and extent of psoriasis during the 3 consultations. The PASI for severe, moderate-severe, mild-moderate cases across time revealed a significant effect of the treatment within weeks, confirming the decreasing scores during the treatment. As well as PASI results, the final DLQI score showed a sensible reduction from mean =6.716 (at week 0) to 6.252 (at week 2), 4.015 (at week 6) and 2.407 (at week 10) signifying a 64.2% reduction of the initial score. This study demonstrates that Dr. Michaels® (Soratinex®) products, an Australian series of herbal-based skin products is effective for the treatment of psoriasis. This treatment also significantly improves patient’s quality of life.

• MeSH
• kvalita života * MeSH
• lidé MeSH
• péče o kůži metody   MeSH
• psoriáza psychologie   terapie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• Geografické názvy
• Austrálie MeSH

The aim of the study was to investigate the efficacy and safety of Michaels® (Soratinex®) remedies in patients suffering from chronic plaque psoriasis in a Czech population. Seventy-five (34 female/41 male) patients, aged 18-72 years old (mean age: 38.5 years) with mild to severe plaque psoriasis participated in the study. The products, including cleansing gel, ointment and skin conditioner, containing fruit acid complex, herbal oils and emulsifiers, were used twice daily and in the same manner for all the skin lesions. The study period was eight weeks. Histologic variables and various blood picture parameters, including FW, glucose, cholesterol, triacylglyceroles, bilirubin, GMT, ALT, AST, creatinine, uric acid and urea in blood were monitored, before and after therapy with Michaels® (Soratinex®) treatment. Assessment, using the Psoriasis Activity Severity Index (PASI) scores and photographic analysis, was done at time 0, and after 2, 4, 6 and 8 weeks. Patient’s improvement was determined by the percentage reduction of the PASI scores. Side effects and tolerability were also evaluated. After 8 weeks using Dr Michaels® (Soratinex®) treatment course, 5 patients had a moderate improvement, with the resolution of 25-50% of skin lesions; 11 patients showed a good improvement, with the resolution of 51-75% of lesions. Another 50 patients had an outstanding improvement, with the regression of 76-100% of lesions. Only 4 patients did not achieve an improvement of psoriasis. Six patients experienced folliculitis, which resolved without cessation of treatment. Three patients worsened and discontinued treatment. Six patients dropped out because of non-compliance. The blood results and histologic findings were all normal. Our investigation shows that Dr Michaels® (Soratinex®) products can be safely and successfully used in the treatment of chronic plaque psoriasis.

• MeSH
• aplikace lokální MeSH
• dospělí MeSH
• emulgátory aplikace a dávkování   terapeutické užití   MeSH
• fytoterapie * MeSH
• lidé středního věku MeSH
• lidé MeSH
• masti aplikace a dávkování   terapeutické užití   MeSH
• mladiství MeSH
• mladý dospělý MeSH
• péče o kůži metody   MeSH
• psoriáza farmakoterapie   MeSH
• senioři MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• Geografické názvy
• Česká republika MeSH
• Názvy látek
• emulgátory MeSH
• masti MeSH

Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatinex®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatinex®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatinex®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatinex®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatinex®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.

• MeSH
• aplikace kožní MeSH
• diabetes mellitus 2. typu komplikace   MeSH
• fytoterapie * MeSH
• intertrigo komplikace   farmakoterapie   patologie   MeSH
• kandidóza kožní komplikace   farmakoterapie   patologie   MeSH
• komplementární terapie metody   MeSH
• kůže účinky léků   patologie   MeSH
• lidé MeSH
• masti aplikace a dávkování   terapeutické užití   MeSH
• obezita komplikace   MeSH
• péče o kůži metody   MeSH
• senioři MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• Názvy látek
• masti MeSH

Lamellar ichthyosis (LI) is a genetically heterogeneous group of disorders of keratinization that are inherited in an autosomal recessive fashion, occurring in approximately 1 in 300,000 live births. The treatment of the large, dark, plate-like scales that characterize the classic manifestation of the disease are still a challenge. The aim of this study was to evaluate the efficacy and tolerability of Dr. Michaels® skin-care products for the management of LI. A multi-centre European prospective study was conducted, including 10 patients (3 female/7 male) with lamellar ichthyosis, aged 38-54 years old (mean age: 46). Each patient had been treated with emollients plus other different systemic therapies, such as corticosteroids, Cyclosporin A or retinoids in the past. All patients were treated with Dr Michaels® product family including both topical and oral herbal supplements. The topical treatments used were the cleansing gel, activator formula and ointment. The oral medications were PSC 200, PSC 400 and PSC 900. Within 3 weeks of initiation of treatment, there were improvements observed on the skin including a reduction in scaling, fissuring, and intensity in erythema and pruritus with thinning of the hyperkeratotic plate. After 12-15 weeks, most of the plates and scales had been removed to reveal a normalised skin colour. Evidence of hair, eyelash and eyebrow growth was observed. There was partial nail resolution with a reduction in subungual hyperkeratosis. No adverse reactions were observed. Our patients showed excellent symptomatic response to treatment within a 14-week period, follow-up by an on-going regular assessment on a quarterly basis. The results show that Dr Michaels® product family is an effective and safe treatment option for LI.

• MeSH
• dospělí MeSH
• fytoterapie metody   MeSH
• kůže účinky léků   MeSH
• lamelární ichtyóza dietoterapie   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• masti aplikace a dávkování   terapeutické užití   MeSH
• péče o kůži metody   MeSH
• potravní doplňky * MeSH
• prospektivní studie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• multicentrická studie MeSH
• Názvy látek
• masti MeSH